Effervescent Morphine Results in Faster Relief of Breakthrough Pain in Patients Compared to Immediate Release Morphine Sulfate Tablet
▪ : Morphine tablets have been formulated to produce an easily ingested effervescent solution when placed in water. It was hypothesized that an aqueous solution would result in fast gastrointestinal transit with a more rapid onset of action compared to immediate release morphine sulfate (IRMS), whi...
Gespeichert in:
| Veröffentlicht in: | Pain practice 2007-12, Vol.7 (4), p.324-331 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 331 |
|---|---|
| container_issue | 4 |
| container_start_page | 324 |
| container_title | Pain practice |
| container_volume | 7 |
| creator | Freye, Enno Levy, Joseph Victor Braun, Dagmar |
| description | ▪ : Morphine tablets have been formulated to produce an easily ingested effervescent solution when placed in water. It was hypothesized that an aqueous solution would result in fast gastrointestinal transit with a more rapid onset of action compared to immediate release morphine sulfate (IRMS), which would be especially beneficial in treating breakthrough pain (BTP). In an open‐label safety and efficacy study, effervescent morphine was given to 76 chronic cancer pain patients for treatment of BTP evaluating time until pain relief, global satisfaction and side effects. Results were compared to those obtained using an IRMS formulation in a preceding run‐in period. For BTP, a mean dose of 28 mg of effervescent morphine (range 10–80 mg) resulted in a highly significant reduction of pain score (mean 7.8 to mean 3.2; P |
| doi_str_mv | 10.1111/j.1533-2500.2007.00157.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68530386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68530386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3457-ae6e53e7f1460e68250f72a9fc4db5e1abb1e5654e94113ce46c35951ad16a113</originalsourceid><addsrcrecordid>eNqNUcFu1DAQtRCIlsIvIJ-4Jdjr2E4OHMqqW4oKRG0RiIvlZMest8lmsR3YfgD_zaS7aq9YlmY0894bzTxCKGc5x_d2nXMpRDaTjOUzxnTOGJc63z0hxw-Np_c5yzQr5RF5EeMaQboS4jk5wlgqLqtj8vfMOQi_IbawSfTTELYrvwF6BXHsUqR-Qxc2JghY6Tw4Ojj6PoC9TaswjD9XtLYIwV_b5FEh0vnQb22AJU0Dveh7WHqbJr0ObITHAddj56bGjW06SC_JM2e7CK8O8YR8XZzdzD9kl1_OL-anl1krCqkzCwqkAO14oRioEtd0emYr1xbLRgK3TcNBKllAVXAuWihUK2QluV1yZbFyQt7sdbdh-DVCTKb3uHnX2Q0MYzSqxIuJUiGw3APbMMQYwJlt8L0Nd4YzM1lg1ma6tJkubSYLzL0FZofU14cZY4PrPxIPN0fAuz3gj-_g7r-FTX1aX2GG_GzP92jM7oFvw61RWmhpvn0-N9flQuofH2vzXfwD7kKlkA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68530386</pqid></control><display><type>article</type><title>Effervescent Morphine Results in Faster Relief of Breakthrough Pain in Patients Compared to Immediate Release Morphine Sulfate Tablet</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Freye, Enno ; Levy, Joseph Victor ; Braun, Dagmar</creator><creatorcontrib>Freye, Enno ; Levy, Joseph Victor ; Braun, Dagmar</creatorcontrib><description>▪ : Morphine tablets have been formulated to produce an easily ingested effervescent solution when placed in water. It was hypothesized that an aqueous solution would result in fast gastrointestinal transit with a more rapid onset of action compared to immediate release morphine sulfate (IRMS), which would be especially beneficial in treating breakthrough pain (BTP). In an open‐label safety and efficacy study, effervescent morphine was given to 76 chronic cancer pain patients for treatment of BTP evaluating time until pain relief, global satisfaction and side effects. Results were compared to those obtained using an IRMS formulation in a preceding run‐in period. For BTP, a mean dose of 28 mg of effervescent morphine (range 10–80 mg) resulted in a highly significant reduction of pain score (mean 7.8 to mean 3.2; P < 0.001). Efficacy was not different from that observed with IRMS. However, mean time until sufficient pain relief was significantly shorter than with IRMS (13 ± 5.6 vs. 27 ± 4.4 minutes; P < 0.01). The incidence of side effects was similar with the new morphine formulation and with IRMS. There was no relationship between the previous dose of the daily opioid and the effective dose of effervescent morphine. The dose for treatment of BTP was determined by individual titration and not predicted by the dose taken with the basic pain medication. Compared to IRMS, overall satisfaction for effervescent morphine was rated “superior” by 16.7%, and “better” by 63.2% of patients. Effervescent morphine offers an alternative for management of breakthrough cancer pain compared with the commonly used IRMS. ▪</description><identifier>ISSN: 1530-7085</identifier><identifier>EISSN: 1533-2500</identifier><identifier>DOI: 10.1111/j.1533-2500.2007.00157.x</identifier><identifier>PMID: 17986159</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analgesics, Opioid - administration & dosage ; Analgesics, Opioid - pharmacokinetics ; breakthrough pain ; cancer pain ; Delayed-Action Preparations ; effervescent morphine ; Female ; Humans ; Intestinal Absorption ; Male ; Middle Aged ; Morphine - administration & dosage ; Morphine - pharmacokinetics ; morphine immediate release ; Neoplasms - complications ; Pain - drug therapy ; Tablets ; Time Factors ; Treatment Outcome</subject><ispartof>Pain practice, 2007-12, Vol.7 (4), p.324-331</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3457-ae6e53e7f1460e68250f72a9fc4db5e1abb1e5654e94113ce46c35951ad16a113</citedby><cites>FETCH-LOGICAL-c3457-ae6e53e7f1460e68250f72a9fc4db5e1abb1e5654e94113ce46c35951ad16a113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1533-2500.2007.00157.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1533-2500.2007.00157.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17986159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Freye, Enno</creatorcontrib><creatorcontrib>Levy, Joseph Victor</creatorcontrib><creatorcontrib>Braun, Dagmar</creatorcontrib><title>Effervescent Morphine Results in Faster Relief of Breakthrough Pain in Patients Compared to Immediate Release Morphine Sulfate Tablet</title><title>Pain practice</title><addtitle>Pain Pract</addtitle><description>▪ : Morphine tablets have been formulated to produce an easily ingested effervescent solution when placed in water. It was hypothesized that an aqueous solution would result in fast gastrointestinal transit with a more rapid onset of action compared to immediate release morphine sulfate (IRMS), which would be especially beneficial in treating breakthrough pain (BTP). In an open‐label safety and efficacy study, effervescent morphine was given to 76 chronic cancer pain patients for treatment of BTP evaluating time until pain relief, global satisfaction and side effects. Results were compared to those obtained using an IRMS formulation in a preceding run‐in period. For BTP, a mean dose of 28 mg of effervescent morphine (range 10–80 mg) resulted in a highly significant reduction of pain score (mean 7.8 to mean 3.2; P < 0.001). Efficacy was not different from that observed with IRMS. However, mean time until sufficient pain relief was significantly shorter than with IRMS (13 ± 5.6 vs. 27 ± 4.4 minutes; P < 0.01). The incidence of side effects was similar with the new morphine formulation and with IRMS. There was no relationship between the previous dose of the daily opioid and the effective dose of effervescent morphine. The dose for treatment of BTP was determined by individual titration and not predicted by the dose taken with the basic pain medication. Compared to IRMS, overall satisfaction for effervescent morphine was rated “superior” by 16.7%, and “better” by 63.2% of patients. Effervescent morphine offers an alternative for management of breakthrough cancer pain compared with the commonly used IRMS. ▪</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analgesics, Opioid - administration & dosage</subject><subject>Analgesics, Opioid - pharmacokinetics</subject><subject>breakthrough pain</subject><subject>cancer pain</subject><subject>Delayed-Action Preparations</subject><subject>effervescent morphine</subject><subject>Female</subject><subject>Humans</subject><subject>Intestinal Absorption</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morphine - administration & dosage</subject><subject>Morphine - pharmacokinetics</subject><subject>morphine immediate release</subject><subject>Neoplasms - complications</subject><subject>Pain - drug therapy</subject><subject>Tablets</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1530-7085</issn><issn>1533-2500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUcFu1DAQtRCIlsIvIJ-4Jdjr2E4OHMqqW4oKRG0RiIvlZMest8lmsR3YfgD_zaS7aq9YlmY0894bzTxCKGc5x_d2nXMpRDaTjOUzxnTOGJc63z0hxw-Np_c5yzQr5RF5EeMaQboS4jk5wlgqLqtj8vfMOQi_IbawSfTTELYrvwF6BXHsUqR-Qxc2JghY6Tw4Ojj6PoC9TaswjD9XtLYIwV_b5FEh0vnQb22AJU0Dveh7WHqbJr0ObITHAddj56bGjW06SC_JM2e7CK8O8YR8XZzdzD9kl1_OL-anl1krCqkzCwqkAO14oRioEtd0emYr1xbLRgK3TcNBKllAVXAuWihUK2QluV1yZbFyQt7sdbdh-DVCTKb3uHnX2Q0MYzSqxIuJUiGw3APbMMQYwJlt8L0Nd4YzM1lg1ma6tJkubSYLzL0FZofU14cZY4PrPxIPN0fAuz3gj-_g7r-FTX1aX2GG_GzP92jM7oFvw61RWmhpvn0-N9flQuofH2vzXfwD7kKlkA</recordid><startdate>200712</startdate><enddate>200712</enddate><creator>Freye, Enno</creator><creator>Levy, Joseph Victor</creator><creator>Braun, Dagmar</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200712</creationdate><title>Effervescent Morphine Results in Faster Relief of Breakthrough Pain in Patients Compared to Immediate Release Morphine Sulfate Tablet</title><author>Freye, Enno ; Levy, Joseph Victor ; Braun, Dagmar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3457-ae6e53e7f1460e68250f72a9fc4db5e1abb1e5654e94113ce46c35951ad16a113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analgesics, Opioid - administration & dosage</topic><topic>Analgesics, Opioid - pharmacokinetics</topic><topic>breakthrough pain</topic><topic>cancer pain</topic><topic>Delayed-Action Preparations</topic><topic>effervescent morphine</topic><topic>Female</topic><topic>Humans</topic><topic>Intestinal Absorption</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morphine - administration & dosage</topic><topic>Morphine - pharmacokinetics</topic><topic>morphine immediate release</topic><topic>Neoplasms - complications</topic><topic>Pain - drug therapy</topic><topic>Tablets</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freye, Enno</creatorcontrib><creatorcontrib>Levy, Joseph Victor</creatorcontrib><creatorcontrib>Braun, Dagmar</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pain practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freye, Enno</au><au>Levy, Joseph Victor</au><au>Braun, Dagmar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effervescent Morphine Results in Faster Relief of Breakthrough Pain in Patients Compared to Immediate Release Morphine Sulfate Tablet</atitle><jtitle>Pain practice</jtitle><addtitle>Pain Pract</addtitle><date>2007-12</date><risdate>2007</risdate><volume>7</volume><issue>4</issue><spage>324</spage><epage>331</epage><pages>324-331</pages><issn>1530-7085</issn><eissn>1533-2500</eissn><abstract>▪ : Morphine tablets have been formulated to produce an easily ingested effervescent solution when placed in water. It was hypothesized that an aqueous solution would result in fast gastrointestinal transit with a more rapid onset of action compared to immediate release morphine sulfate (IRMS), which would be especially beneficial in treating breakthrough pain (BTP). In an open‐label safety and efficacy study, effervescent morphine was given to 76 chronic cancer pain patients for treatment of BTP evaluating time until pain relief, global satisfaction and side effects. Results were compared to those obtained using an IRMS formulation in a preceding run‐in period. For BTP, a mean dose of 28 mg of effervescent morphine (range 10–80 mg) resulted in a highly significant reduction of pain score (mean 7.8 to mean 3.2; P < 0.001). Efficacy was not different from that observed with IRMS. However, mean time until sufficient pain relief was significantly shorter than with IRMS (13 ± 5.6 vs. 27 ± 4.4 minutes; P < 0.01). The incidence of side effects was similar with the new morphine formulation and with IRMS. There was no relationship between the previous dose of the daily opioid and the effective dose of effervescent morphine. The dose for treatment of BTP was determined by individual titration and not predicted by the dose taken with the basic pain medication. Compared to IRMS, overall satisfaction for effervescent morphine was rated “superior” by 16.7%, and “better” by 63.2% of patients. Effervescent morphine offers an alternative for management of breakthrough cancer pain compared with the commonly used IRMS. ▪</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>17986159</pmid><doi>10.1111/j.1533-2500.2007.00157.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1530-7085 |
| ispartof | Pain practice, 2007-12, Vol.7 (4), p.324-331 |
| issn | 1530-7085 1533-2500 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68530386 |
| source | Wiley-Blackwell Journals; MEDLINE |
| subjects | Adult Aged Aged, 80 and over Analgesics, Opioid - administration & dosage Analgesics, Opioid - pharmacokinetics breakthrough pain cancer pain Delayed-Action Preparations effervescent morphine Female Humans Intestinal Absorption Male Middle Aged Morphine - administration & dosage Morphine - pharmacokinetics morphine immediate release Neoplasms - complications Pain - drug therapy Tablets Time Factors Treatment Outcome |
| title | Effervescent Morphine Results in Faster Relief of Breakthrough Pain in Patients Compared to Immediate Release Morphine Sulfate Tablet |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T22%3A59%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effervescent%20Morphine%20Results%20in%20Faster%20Relief%20of%20Breakthrough%20Pain%20in%20Patients%20Compared%20to%20Immediate%20Release%20Morphine%20Sulfate%20Tablet&rft.jtitle=Pain%20practice&rft.au=Freye,%20Enno&rft.date=2007-12&rft.volume=7&rft.issue=4&rft.spage=324&rft.epage=331&rft.pages=324-331&rft.issn=1530-7085&rft.eissn=1533-2500&rft_id=info:doi/10.1111/j.1533-2500.2007.00157.x&rft_dat=%3Cproquest_cross%3E68530386%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68530386&rft_id=info:pmid/17986159&rfr_iscdi=true |